Head-to-head evidence
Rademikibart vs stapokibart
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Atopic Dermatitis
Shared mechanism: IL-4R-alpha · full Atopic Dermatitis pipeline
Rademikibart
Developed by Simcere Pharmaceutical and partners
NCT05017480 · Phase 2 · completed
The study was randomized, quadruple-blind, placebo-controlled, and included 330 participants, with a clinical primary endpoint based on validated Investigator Global Assessment. Although the reported primary response favored rademikibart (29.0% vs 5.9%), the registry does not state whether the primary comparison was statistically significant, so the result remains unclear.
stapokibart
Developed by CSPC ZhongQi Pharmaceutical Technology Co., Ltd. and partners
NCT05265923 · Phase 3 · completed
In this randomized, double-blind, placebo-controlled Phase 3 trial in 500 adults with moderate-to-severe atopic dermatitis, significantly more patients receiving stapokibart achieved at least a 75% reduction in eczema severity at 16 weeks than those on placebo (66.9% vs 25.8%).
Next expected readout: February 2027 · NCT07106372 (registry estimate)
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Rademikibart's landscape · stapokibart's landscape